What is Lifesci Capital's Estimate for DNTH Q3 Earnings?

Key Points

• Lifesci Capital has revised its Q3 2025 earnings per share estimate for Dianthus Therapeutics to ($0.88), down from ($0.87).
• Despite the bearish forecast, the stock has a consensus "Buy" rating among analysts, with an average target price of $53.00.
• Dianthus Therapeutics recently reported Q2 earnings of ($0.88) per share, missing the consensus estimate of ($0.86) by ($0.02).

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Equities researchers at Lifesci Capital cut their Q3 2025 earnings per share (EPS) estimates for Dianthus Therapeutics in a report released on Wednesday, August 13th. Lifesci Capital analyst R. Katkhuda now forecasts that the company will post earnings of ($0.88) per share for the quarter, down from their prior forecast of ($0.87). The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. Lifesci Capital also issued estimates for Dianthus Therapeutics' Q4 2025 earnings at ($0.90) EPS and FY2025 earnings at ($3.49) EPS.

A number of other equities research analysts have also recently issued reports on DNTH. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. William Blair assumed coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an "outperform" rating for the company. Finally, Robert W. Baird cut their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of "Buy" and an average price target of $53.00.

Dianthus Therapeutics Trading Up 2.4%

Shares of NASDAQ:DNTH traded up $0.49 during trading on Friday, reaching $20.74. 280,117 shares of the stock were exchanged, compared to its average volume of 326,570. Dianthus Therapeutics has a 12 month low of $13.36 and a 12 month high of $32.27. The firm has a market cap of $667.62 million, a PE ratio of -6.38 and a beta of 1.43. The stock has a 50-day moving average price of $19.49 and a 200-day moving average price of $19.98.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DNTH. JPMorgan Chase & Co. raised its position in Dianthus Therapeutics by 14.0% during the fourth quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company's stock valued at $264,000 after purchasing an additional 1,490 shares in the last quarter. Invesco Ltd. raised its position in Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock valued at $251,000 after purchasing an additional 790 shares in the last quarter. Legal & General Group Plc raised its position in Dianthus Therapeutics by 23.7% during the fourth quarter. Legal & General Group Plc now owns 12,319 shares of the company's stock valued at $269,000 after purchasing an additional 2,363 shares in the last quarter. Barclays PLC raised its position in Dianthus Therapeutics by 2.6% during the fourth quarter. Barclays PLC now owns 42,766 shares of the company's stock valued at $933,000 after purchasing an additional 1,082 shares in the last quarter. Finally, Walleye Capital LLC raised its position in Dianthus Therapeutics by 176.3% during the fourth quarter. Walleye Capital LLC now owns 82,890 shares of the company's stock valued at $1,807,000 after purchasing an additional 52,890 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.